US-based biopharmaceutical company Biofrontera has finished enrolling subjects in its multicentre Phase III trial of Ameluz ...

This key catalyst highlights Biofrontera's commitment to expanding treatment options for actinic keratoses, a condition affecting millions worldwide. Currently, BFRI is trading at $1.05 up by 3.96 ...

Australia: Researchers have found in a small study that immune checkpoint inhibitors (ICIs) used for cancer treatment ...

Q: AN seborrheic keratoses give you back ache? My back is covered in it and I’m getting pain from about where my lungs are up to my shoulders. Seborrheic keratoses are harmless warty spots that ...

Biofrontera announced the enrollment of the final patient in its Phase 3 clinical trial evaluating Ameluz for the treatment of mild to moderate ...

What Are Actinic Keratoses? Actinic keratoses (AKs) are a common skin condition characterized by rough, red, scaly patches, crusts, or sores on the top layer of skin (see Figures 1 & 2).

Opens in a new tab or window Use of immune checkpoint inhibitors for cancer was associated with a significant reduction in actinic keratoses in a small study. The effect was greatest in younger ...

Use of immune checkpoint inhibitor (ICI) therapy for cancer was associated with a significant reduction in actinic keratoses in a small prospective cohort study, indicating potential as an immuno ...

Dermatoscope imaging processed with AI has been in use in the UK for 4 years with accuracy shown to be at least equal to ...

Deborah S. Sarnoff, M.D., talks about the recent breakthrough treatments that are paving the way to treat patients with ...

Biofrontera (NASDAQ:BFRI – Get Free Report) is projected to release its earnings data before the market opens on Thursday, March 13th. Analysts expect Biofrontera to post earnings of ($0.07) per share ...